2nd Quarter - Report

VERTEX PHARMACEUTICALS INCORPORATED for VERTEX PHARMACEUTICALS INCORPORATED

Firm
Client
Income
—
Expenses
$630,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

General education about federal policies impacting pharmaceutical development, approval, and reimbursement; Patient access to non-opioid pain medicines; Issues related to FDA drug approval process; Copay accumulators and maximizers, HELP Copays Act (HR 830, S. 1375); General education about Alternative Funding Programs; Pandemic All-Hazards Preparedness Act reauthorization, including new authorities requested by FDA.

LobbyistCovered position, as disclosed
KRISTIN RICHTER New Int Rep. Coble (2008); Int Com on E&C (2011); SA Rep. Stearns (2012); Int LC L Concl. Rep. Bilirakis (2014-2016); L Concl. LD Rep. Griffith (2016-2019); Concl Com on E&C (2019-2023)
MATTHEW O SCHUMAKER —
SWARNA VALLURUPALLI New Health and Tax Fellow Sen Finance Com (2012-2013); Health and Tax Concl. Sen Hirono (2013-2017); Health Concl. Senior Concl. Sen. Menendez (2017-2023) - *Did not lobby Senate
SAMANTHA VENTIMIGLIA —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 1375 (118th), H.R. 830 (118th)

Taxation/Internal Revenue Code TAX

Issues related to corporate and international tax policy and research and development tax credits, American Innovation and R&D Competitiveness Act (H.R. 2673) and American Innovation and Jobs Act (S. 866)

LobbyistCovered position, as disclosed
MATTHEW O SCHUMAKER —
SWARNA VALLURUPALLI New Health and Tax Fellow Sen Finance Com (2012-2013); Health and Tax Concl. Sen Hirono (2013-2017); Health Concl. Senior Concl. Sen. Menendez (2017-2023) - *Did not lobby Senate

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 2673 (118th), S. 866 (118th)

Budget/Appropriations BUD

Issues related to funding for the Food and Drug Administration - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act; General education about policies to improve outcomes for patients with APOL-1 kidney disease.

LobbyistCovered position, as disclosed
MATTHEW O SCHUMAKER —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Medicare/Medicaid MMM

General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Implementation of P.L. 117-169 provisions related to Medicare prescription drugs. Education about non-opioid pain therapies and Medicare beneficiary access to non-opioid medicines.

LobbyistCovered position, as disclosed
KRISTIN RICHTER New Int Rep. Coble (2008); Int Com on E&C (2011); SA Rep. Stearns (2012); Int LC L Concl. Rep. Bilirakis (2014-2016); L Concl. LD Rep. Griffith (2016-2019); Concl Com on E&C (2019-2023)
MATTHEW O SCHUMAKER —
SWARNA VALLURUPALLI New Health and Tax Fellow Sen Finance Com (2012-2013); Health and Tax Concl. Sen Hirono (2013-2017); Health Concl. Senior Concl. Sen. Menendez (2017-2023) - *Did not lobby Senate
SAMANTHA VENTIMIGLIA —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.